羟基脲治疗的老年经典型骨髓增殖性肿瘤患者的第二恶性肿瘤
该回顾性队列研究纳入2010至2017年诊断为MPN的年龄≥66岁患者4023例,评估羟基脲(HU)与第二恶性肿瘤(SM)风险的关系。中位随访3.25年后,HU使用者与非使用者的SM累积发生率分别为19.88%与22.31%(P<.01),AML/MDS风险无显著差异(HR 1.33,95%CI 0.77-2.29,P=.30)。结果提示HU不增加老年MPN患者的SM风险。
要点
- HU使用者SM累积发生率为19.88%,非使用者为22.31%(P<.01)。
- HU使用者与非使用者AML/MDS风险无显著差异(HR 1.33,95%CI 0.77-2.29,P=.30)。
- 结果提示HU不增加老年MPN患者的第二恶性肿瘤风险。
核心结论
- 结果提示羟基脲不增加老年骨髓增殖性肿瘤患者的第二恶性肿瘤风险。
研究设计与样本
- 回顾性队列研究,纳入2010至2017年诊断为MPN的年龄≥66岁患者,数据来自监测、流行病学和最终结果(SEER)Medicare链接数据库。
- 共纳入4023例患者,其中真性红细胞增多症1688例、原发性血小板增多症1976例、骨髓纤维化359例,诊断时中位年龄77岁(四分位距71-83岁)。
- 采用多变量竞争风险分析校正患者特征,评估羟基脲对第二恶性肿瘤发生的影响。
主要发现
- 中位随访3.25年(四分位距2.10-5.00年)后,489例患者发生第二恶性肿瘤,其中实体瘤346例、淋系肿瘤73例、髓系肿瘤70例。
- 羟基脲使用者(2683例)第二恶性肿瘤累积发生率为19.88%(95%CI 17.16%-22.75%),非使用者(1340例)为22.31%(95%CI 17.51%-27.47%),Gray检验P<.01。
- 羟基脲使用者与非使用者之间实体瘤或血液系统第二恶性肿瘤的发生率无显著差异,包括AML/MDS(HR 1.33,95%CI 0.77-2.29,P=.30)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary and secondary myelofibrosis (MF), are known to have an increased risk of second malignancies (SMs). Hydroxyurea (HU) is a guideline-recommended cytoreductive therapy for patients at high risk for MPNs. Controversy exists as to whether HU use is associated with a higher risk of SMs, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We conducted a retrospective cohort study of older patients diagnosed with MPN (age ≥66 years) between 2010 and 2017 and included the data in the Surveillance, Epidemiology, and End Results Medicare-linked database. Multivariable competing risk analyses adjusting for patient characteristics were used to assess the impact of HU on the development of SM. We identified 4023 patients (1688 with PV, 1976 with ET, and 359 with MF) with a median age of 77 (interquartile range [IQR], 71-83) years at the time of MPN diagnosis. After a median follow-up of 3.25 (IQR, 2.10-5.00) years, 489 patients developed an SM (346 solid, 73 lymphoid, and 70 myeloid malignancies). The cumulative incidence probability of SM was 19.88% (95% confidence interval [CI], 17.16%-22.75%) among 2683 HU users and 22.31% (95% CI, 17.51%-27.47%) among 1340 nonusers, respectively (Gray's test, P < .01). We did not identify significant differences in the incidence of solid or hematologic SMs, including AML/MDS (hazard ratio, 1.33; 95% CI, 0.77-2.29; P = .30), between HU users and nonusers. Our results suggest that the use of HU does not increase the risk of SM in older patients with MPN.
引用
- Wang R, Shallis RM, Stempel JM, et al. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Adv. 2023. PMID: 35917456. doi:10.1182/bloodadvances.2022008259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。